RU2016102346A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016102346A3 RU2016102346A3 RU2016102346A RU2016102346A RU2016102346A3 RU 2016102346 A3 RU2016102346 A3 RU 2016102346A3 RU 2016102346 A RU2016102346 A RU 2016102346A RU 2016102346 A RU2016102346 A RU 2016102346A RU 2016102346 A3 RU2016102346 A3 RU 2016102346A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13968708P | 2008-12-22 | 2008-12-22 | |
| US61/139,687 | 2008-12-22 | ||
| US16449109P | 2009-03-30 | 2009-03-30 | |
| US61/164,491 | 2009-03-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011127333A Division RU2630969C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение боли |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016102346A RU2016102346A (ru) | 2018-11-20 |
| RU2016102346A3 true RU2016102346A3 (https=) | 2019-07-29 |
| RU2712166C2 RU2712166C2 (ru) | 2020-01-24 |
Family
ID=42286785
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011127333A RU2630969C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение боли |
| RU2016102346A RU2712166C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение боли |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011127333A RU2630969C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение боли |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8475796B2 (https=) |
| EP (2) | EP2387418B1 (https=) |
| JP (3) | JP5674677B2 (https=) |
| KR (1) | KR101761324B1 (https=) |
| CN (2) | CN108014335A (https=) |
| AU (2) | AU2009329811B2 (https=) |
| BR (1) | BRPI0918103A2 (https=) |
| CA (1) | CA2747206C (https=) |
| ES (2) | ES2978209T3 (https=) |
| HK (2) | HK1255046A1 (https=) |
| RU (2) | RU2630969C2 (https=) |
| WO (1) | WO2010071923A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102271705A (zh) | 2008-12-22 | 2011-12-07 | 墨尔本大学 | 骨关节炎治疗 |
| CA2747206C (en) * | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| MA37946B1 (fr) * | 2012-09-20 | 2018-09-28 | Morphosys Ag | Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| WO2014068029A1 (en) * | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US20160024200A1 (en) * | 2013-03-14 | 2016-01-28 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
| US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| SG11201901789WA (en) | 2016-09-19 | 2019-03-28 | I Mab | Anti-gm-csf antibodies and uses thereof |
| CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
| CN120093288B (zh) * | 2025-05-08 | 2025-07-11 | 中国农业大学烟台研究院 | 一种牲畜生理行为监测方法及系统 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0482086A1 (en) * | 1989-07-14 | 1992-04-29 | Schering Corporation | Antagonists of gm-csf derived from the carboxyl terminus |
| EP0486572B1 (en) | 1989-08-11 | 1998-01-07 | Amrad Corporation Limited | Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| AU5611394A (en) * | 1992-11-19 | 1994-06-08 | Dana-Farber Cancer Institute | Antibodies for gm-csf receptor and uses thereof |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| AUPP525198A0 (en) | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| SE0102067D0 (sv) * | 2001-06-11 | 2001-06-11 | A & Science Invest Ab | Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation |
| EP1442132A2 (en) | 2001-10-26 | 2004-08-04 | Novartis AG | Methods for the treatment of osteoarthritis and compositions thereof |
| JP2006500905A (ja) | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| AU2002950957A0 (en) * | 2002-08-23 | 2002-09-12 | The Walter And Eliza Hall Institute Of Medical Research | A method of treatment and prophylaxis |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US20040241755A1 (en) | 2003-06-02 | 2004-12-02 | Pfizer Inc. | Human cell assay to determine effect of sample compounds on Col2 enhancer expression |
| ES2465141T3 (es) | 2004-03-31 | 2014-06-05 | Kazuwa Nakao | Remedio o medicamento preventivo para la artritis |
| ATE435238T1 (de) | 2004-05-05 | 2009-07-15 | Micromet Ag | Herstellung eines einkettigen fv antikörperfragments |
| BRPI0608281B8 (pt) | 2005-04-18 | 2021-05-25 | Amgen Res Munich Gmbh | anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende |
| RU2447085C2 (ru) * | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| EA200801166A1 (ru) | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
| US7741450B2 (en) | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| MX2008012291A (es) | 2006-03-27 | 2009-01-12 | Medimmune Ltd | Miembro que enlaza al receptor gm-csf. |
| US7741273B2 (en) * | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| EP2101780B1 (en) * | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| WO2008080134A2 (en) | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
| CN101687926A (zh) | 2007-05-23 | 2010-03-31 | 哮喘和气道Crc有限公司 | 中和抗体 |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| WO2009062238A1 (en) | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
| CN104072613A (zh) | 2007-11-13 | 2014-10-01 | Evec股份有限公司 | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 |
| WO2009134805A2 (en) | 2008-04-28 | 2009-11-05 | Kalobios Pharmaceuticals, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| CN102271705A (zh) | 2008-12-22 | 2011-12-07 | 墨尔本大学 | 骨关节炎治疗 |
| CA2747206C (en) * | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| US8609101B2 (en) | 2009-04-23 | 2013-12-17 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies |
-
2009
- 2009-12-21 CA CA2747206A patent/CA2747206C/en active Active
- 2009-12-21 AU AU2009329811A patent/AU2009329811B2/en active Active
- 2009-12-21 ES ES18170226T patent/ES2978209T3/es active Active
- 2009-12-21 RU RU2011127333A patent/RU2630969C2/ru active
- 2009-12-21 JP JP2011541029A patent/JP5674677B2/ja active Active
- 2009-12-21 US US13/140,839 patent/US8475796B2/en active Active
- 2009-12-21 CN CN201711112956.0A patent/CN108014335A/zh active Pending
- 2009-12-21 WO PCT/AU2009/001671 patent/WO2010071923A1/en not_active Ceased
- 2009-12-21 EP EP09833923.7A patent/EP2387418B1/en active Active
- 2009-12-21 KR KR1020117017019A patent/KR101761324B1/ko not_active Expired - Fee Related
- 2009-12-21 CN CN200980151639.7A patent/CN102256621B/zh active Active
- 2009-12-21 EP EP18170226.7A patent/EP3381471B1/en active Active
- 2009-12-21 ES ES09833923.7T patent/ES2685895T3/es active Active
- 2009-12-21 BR BRPI0918103A patent/BRPI0918103A2/pt not_active Application Discontinuation
- 2009-12-21 RU RU2016102346A patent/RU2712166C2/ru active
-
2013
- 2013-05-28 US US13/903,009 patent/US9352034B2/en active Active
-
2014
- 2014-07-04 JP JP2014138170A patent/JP6147704B2/ja active Active
-
2016
- 2016-01-18 AU AU2016200267A patent/AU2016200267B2/en active Active
- 2016-04-29 US US15/142,746 patent/US9834599B2/en not_active Expired - Fee Related
-
2017
- 2017-04-05 JP JP2017074868A patent/JP2017149740A/ja active Pending
-
2018
- 2018-11-07 HK HK18114170.3A patent/HK1255046A1/zh unknown
- 2018-11-09 HK HK18114356.9A patent/HK1255227A1/en unknown